Latest News

Lecanemab Shows Sustained Benefit at 4 Years in Early Alzheimer Disease: AAIC 2025 / Image credit: ©Artur/AdobeStock
Lecanemab Shows Sustained Benefit at 4 Years in Early Alzheimer Disease: AAIC 2025

August 1st 2025

Four-year data show lecanemab slows clinical decline in early Alzheimer disease and maintains a consistent safety profile.

Tirzepatide Proves Noninferiority with Dulaglutide for MACE in Lilly's Landmark Incretin Face-Off / image credit ©MichaelVI/stock.adobe.com
Tirzepatide Proves Noninferiority with Dulaglutide for MACE in Lilly's Landmark Incretin Face-Off

August 1st 2025

Donanemab Showed Sustained Cognitive Benefit Over 3 Years in Early Alzheimer Disease / Image credit: ©LIGHTFIELD STUDIOS/AdobeStock
Donanemab Showed Sustained Cognitive Benefit Over 3 Years in Early Alzheimer Disease

July 30th 2025

Alzheimer's Association Releases First Clinical Guideline on Use of Blood-Based Biomarker Tests / image credit ©ryandi/stock.adobe.com
Alzheimer's Association Releases First Clinical Guideline on Use of Blood-Based Biomarker Tests

July 30th 2025

Remote Cognitive Screening Platform Expands Access to Early Detection / Image credit: ©Visualmind/AdobeStock
Remote Cognitive Screening Platform Expands Access to Early Detection

July 29th 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.